Dian Su

Drug Metabolism and Pharmocokinetics (DPMK)

Dian Su is a Senior Director, DMPK, at Mersana Therapeutics. Her research focuses on antibody-drug conjugates (ADCs). Previously, Dian was a Principal Scientist in the DMPK department at Genentech. Her research was primarily focused on ADC/small molecule/peptide DMPK areas mainly in the pre-clinical stage. Before joining Genentech in 2012, Dian held a postdoctoral position at the NIH Proteomics Research Resource for Integrative Biology in Pacific Northwest National Laboratory. She earned her Ph. D. in Chemistry from Washington University in St. Louis and studied DNA photoproducts and protein-ligand interactions.

Farmyard to Pharma: The Rising Role of Minipigs in Drug Discovery

Minipigs have recently gained prominence as an alternative non-rodent in vivo model for pharmacokinetic (PK), efficacy, and toxicology studies supporting human dose predictions. This article provides an overview of the use of minipigs in small molecule preclinical drug discovery research, tracing their historical background and outlining practical considerations for selecting them in studies focusing on hepatic metabolism, oral bioavailability, CNS penetration, and toxicology. It highlights minipigs' unique advantages and makes a compelling case for their continued use in preclinical research.

Resource

A Cross-Functional Mindset in DMPK

Dian Su’s journey from chemistry and proteomics to the DMPK of drug conjugates Following a different path comes naturally to Dian Su, Senior Director of DMPK at Bicycle Therapeutics. From a childhood in a small village in China’s northeast Shandong province to her work examining the drug metabolism and pharmacokinetics (DMPK) of antibody-drug [...]

Article

Phase I Drug Metabolism

This article explains what Phase I drug metabolism is, contains a poster summarizing common enzyme-mediated drug metabolism reactions, and provides interesting examples of phase I biotransformations and their impact on drug pharmacology. By Drake Anthony Russell , reviewed by Dr. Dian Su and Dr. Julia Shanu-Wilson. Thanks to Hypha Discovery [...]

Resource

Scientific Highlights from 2020’s Drug Discovery Biotech IPOs

Recently, our team at Drug Hunter compiled the lead programs and mechanisms of small molecule and large molecule biotechs that IPO’d in 2020. We asked featured reviewers from our community what stood out to them about the science of this group of companies, and here are some highlights that emerged from the discussion. Any thoughts and [...]

Resource

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >15,000 drug hunters worldwide. Unsubscribe anytime.